Disc Medicine
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 9 in the most recent period (2026/Q3).
- Total institutional ownership fell 18.6 percentage points.
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 103.59% -18.57pp
- Institutions
- 285 +9
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 20 buys · 30 sells
| Name | Role | Stake |
|---|---|---|
| John Quisel | Chief Executive Officer | 0.25% |
| William Savage | Chief Medical Officer | 0.08% |
| Pamela Stephenson | Chief Commercial Officer | 0.04% |
| Rahul Khara | Chief Legal Officer | 0.04% |
| Donald Nicholson | Executive Chairperson | 0.03% |
| Jonathan Yu | Chief Opearating Officer | 0.02% |
| Joanne Bryce | Former Chief Financial Officer | 0.01% |
| Atlas Venture Advisors, Inc. | -- | -- |
| OrbiMed Advisors LLC | -- | -- |
| Access Industries, Inc. | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | William Savage | Chief Medical Officer | Automatic Disposition | -16,035 | $85.09 |
| 2026-10-20 | Atlas Venture Advisors, Inc. | -- | Automatic Disposition | -41,825 | $79.95–80.23 |
| 2026-09-14 | John Quisel | Chief Executive Officer | Derivative Exercise and Retained | +36,000 | $1.01 |
| 2026-09-10 | Kevin Bitterman | Independent Director | Derivative Exercise and Sale | -27,136 | $38.85–70.11 |
| 2026-09-03 | Atlas Venture Advisors, Inc. | -- | Automatic Disposition | -1,689 | $79.96 |
| 2026-09-02 | Atlas Venture Advisors, Inc. | -- | Automatic Disposition | -54,496 | $79.95–80.98 |
| 2026-08-24 | Jonathan Yu | Chief Opearating Officer | Derivative Exercise and Sale | -9,096 | $13.50–83.12 |
| 2026-08-16 | John Quisel | Chief Executive Officer | Derivative Exercise and Sale | -33,000 | $13.50–79.84 |
| 2026-08-11 | Jonathan Yu | Chief Opearating Officer | Derivative Exercise and Sale | -804 | $13.50–82.64 |
| 2026-08-05 | Rahul Khara | Chief Legal Officer | Derivative Exercise and Sale | -5,000 | $14.69–80.00 |
| 2026-07-12 | John Quisel | Chief Executive Officer | Derivative Exercise and Sale | -33,000 | $9.86–76.05 |
| 2026-07-06 | Jonathan Yu | Chief Opearating Officer | Derivative Exercise and Sale | -100 | $13.50–82.50 |
| 2026-06-28 | Rahul Khara | Chief Legal Officer | Derivative Exercise and Sale | -2,500 | $14.69–75.00 |
| 2026-06-25 | Jonathan Yu | Chief Opearating Officer | Derivative Exercise and Sale | -300 | $13.50–72.50 |
| 2026-06-21 | Jonathan Yu | Chief Opearating Officer | Derivative Exercise and Sale | -9,700 | $13.50–72.66 |
| 2026-06-17 | Georges Gemayel | Independent Director | Other Derivative Acquisition | +6,212 | $70.79 |
| 2026-06-17 | Kevin Bitterman | Independent Director | Other Derivative Acquisition | +6,212 | $70.79 |
| 2026-06-17 | Liam Ratcliffe | Independent Director | Other Derivative Acquisition | +6,212 | $70.79 |
| 2026-06-17 | John Quisel | Chief Executive Officer | Derivative Exercise and Sale | -34,000 | $9.86–71.61 |
| 2026-06-17 | Mark Chin | Independent Director | Other Derivative Acquisition | +6,212 | $70.79 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:01:18 · For reference only, not investment advice and not tailored to your situation.
Disc Medicine discussion 0 comments